• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, September 26, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

New leukemia treatment outperforms standard chemotherapies

Bioengineer by Bioengineer
June 8, 2017
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers at The Australian National University (ANU) are working on a new treatment for an aggressive type of leukemia that outperforms standard chemotherapies.

Lead researcher Dr Nadine Hein from The John Curtin School of Medical Research at ANU said researchers have successfully treated highly aggressive acute myeloid leukemia (AML) in mice using the new treatment.

"Not only have we been able to reduce the number of cancer cells, we have been able to reduce the number of cancer stem cells that tend to develop or be resistant to chemotherapy and are thought to be responsible for disease relapse in patients," Dr Hein said.

Dr Hein said researchers used a compound known as CX-5461 to target the protein-making process within the cancer cells.

"We are working towards a treatment that will improve on the current chemotherapy options and improve the patient's prognosis," Dr Hein said

Around 1,000 people are diagnosed with AML in Australia each year and, depending on the patient's age, there is a high rate of mortality with only about 30 percent surviving long term.

Canberra haematologist and ANU Senior Lecturer Dr James D'Rozario said the standard approach to treating AML hasn't changed in over 30 years.

"Novel agents such as CX-5461 with more sophisticated mechanisms of action are desperately required to improve outcomes in patients with this group of illnesses," Dr D'Rozario said.

Professor Ross Hannan, Head of the ACRF Department of Cancer Biology and Therapeutics at JCSMR, said that based on the promising preclinical results, a Phase 1 clinical trial for the treatment of patients with blood cancer has just been completed in Australia. Results are expected to be published later this year.

"Another Phase 1/ Phase 2 clinical trial is underway in Canada for the treatment of patients with solid tumours," Professor Hannan said.

###

The research has been published in Blood: http://www.bloodjournal.org/content/129/21/2882?sso-checked=true

For media assistance, contact Kate Prestt in the ANU media team on +61 2 6125 7979, or email [email protected].

Media Contact

Kate Prestt
[email protected]
61-261-257-979
@ANUmedia

http://www.anu.edu.au/media

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Laser-Dissected Proteomics Reveals Where Immunity Really Lives in Triple-Negative Breast Tumors

September 26, 2026

Lockdowns Curbed Teen Drinking Worldwide, But a New Analysis Reveals Stark Regional Divides

September 26, 2026

Global analysis maps Staphylococcus aureus burden and antibiotic resistance in dairy cow udder infections

September 26, 2026

Loneliness Erodes Bone: Isolation Weakens Male Mice Skeletons but Spares Females

September 26, 2026
Please login to join discussion

POPULAR NEWS

  • Overlapping Genes Evolve by Different Rules in Bacteria and Complex Life

    29 shares
    Share 12 Tweet 7
  • Laser-Dissected Proteomics Reveals Where Immunity Really Lives in Triple-Negative Breast Tumors

    29 shares
    Share 12 Tweet 7
  • Three-Year Campus Study Reveals How Bangkok’s Haze Season Seeps Into University Buildings

    29 shares
    Share 12 Tweet 7
  • Lockdowns Curbed Teen Drinking Worldwide, But a New Analysis Reveals Stark Regional Divides

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Overlapping Genes Evolve by Different Rules in Bacteria and Complex Life

Laser-Dissected Proteomics Reveals Where Immunity Really Lives in Triple-Negative Breast Tumors

Three-Year Campus Study Reveals How Bangkok’s Haze Season Seeps Into University Buildings

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.